Literature DB >> 16791269

Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia.

M Meier1, M L den Boer, J P P Meijerink, M J C Broekhuis, M M C J Passier, E R van Wering, G E Janka-Schaub, R Pieters.   

Abstract

The T-lineage phenotype of childhood acute lymphoblastic leukaemia (ALL) is associated with an increased relapse-risk and in vitro resistance to drugs as compared to a precursor B phenotype. Antiapoptotic isoforms of p73 that lack part of the transactivation (TA) domain (DeltaTA-p73, i.e. p73Deltaex2, p73Deltaex3, p73Deltaex2/3 and DeltaN-p73) may cause resistance to anticancer agents through inhibition of p53 and/or proapoptotic p73 family members (TA-p73). We demonstrate in our study that the expression of total p73 mRNA was higher in childhood T-ALL compared to controls (P=0.004). In T-ALL, the relative contribution of antiapoptotic DeltaTA-p73 (88%) was larger than of proapoptotic TA-p73 (12%). Leukaemic cells of T-ALL patients expressing higher levels of antiapoptotic p73 were more resistant to the DNA-damaging drug daunorubicin compared to cells of patients with low or negative expression or these isoforms (P(trend)=0.045). Interestingly, p73Deltaex2 was the most abundantly expressed antiapoptotic isoform in daunorubicin-resistant patient cells (44% of total p73). No association was found between high expression of proapoptotic TA-p73 or antiapoptotic DeltaTA-p73 and relapse-risk. Our results suggest that childhood T-ALL is associated with a high expression of DeltaTA-p73. These isoforms may play a role in cellular resistance to DNA-damaging drugs in children at initial diagnosis of T-ALL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16791269     DOI: 10.1038/sj.leu.2404288

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

Review 1.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

Review 2.  Clinical implications of the deregulated TP73 isoforms expression in cancer.

Authors:  N Rodríguez; A Peláez; R Barderas; G Domínguez
Journal:  Clin Transl Oncol       Date:  2017-12-11       Impact factor: 3.405

3.  High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia.

Authors:  Antonio R Lucena-Araujo; Haesook T Kim; Carolina Thomé; Rafael H Jacomo; Raul A Melo; Rosane Bittencourt; Ricardo Pasquini; Katia Pagnano; Ana Beatriz F Glória; Maria de Lourdes Chauffaille; Melina Athayde; Carlos S Chiattone; Ingrid Mito; Rodrigo Bendlin; Carmino Souza; Cristina Bortolheiro; Juan L Coelho-Silva; Stanley L Schrier; Martin S Tallman; David Grimwade; Arnold Ganser; Nancy Berliner; Raul C Ribeiro; Francesco Lo-Coco; Bob Löwenberg; Miguel A Sanz; Eduardo M Rego
Journal:  Blood       Date:  2015-10-01       Impact factor: 22.113

Review 4.  Tumour suppressor genes in chemotherapeutic drug response.

Authors:  Dulcie Lai; Stacy Visser-Grieve; Xiaolong Yang
Journal:  Biosci Rep       Date:  2012-08       Impact factor: 3.840

5.  p53 Family: Role of Protein Isoforms in Human Cancer.

Authors:  Jinxiong Wei; Elena Zaika; Alexander Zaika
Journal:  J Nucleic Acids       Date:  2011-10-09

6.  ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype.

Authors:  Antonio R Lucena-Araujo; Juan L Coelho-Silva; Diego A Pereira-Martins; Carolina Thomé; Priscila S Scheucher; Ana P Lange; Helder H Paiva; Benjamin T Hemmelgarn; Mariana C Morais-Sobral; Elisa A Azevedo; Pedro L Franca-Neto; Rafael F Franca; Cleide L Silva; Alexandre Krause; Eduardo M Rego
Journal:  Oncotarget       Date:  2017-01-31

Review 7.  The p53 family member p73 in the regulation of cell stress response.

Authors:  Svetlana Zvereva; Aleksandra Dalina; Igor Blatov; Julian M Rozenberg; Ilya Zubarev; Daniil Luppov; Alexander Bessmertnyi; Alexander Romanishin; Lamak Alsoulaiman; Vadim Kumeiko; Alexander Kagansky; Gerry Melino; Carlo Ganini; Nikolai A Barlev
Journal:  Biol Direct       Date:  2021-11-08       Impact factor: 4.540

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.